WESTBURY, NY - Apr 12, 2018 - BioIVT, a leading provider of biospecimens and related services, today announced that it will be focusing on best practices for assessing T cell-mediated cytotoxicity at the American Association for Cancer Research (AACR) Annual Meeting. This year’s conference will be held from Apr. 14-18 at McCormick Place in Chicago, IL.

“Oncology researchers are continuing to actively investigate methods of strengthening patients’ immune responses to help combat their cancer,” said Clifford M. Raynor, Senior Vice President of Clinical Operations at BioIVT. “As interest in T cell immunotherapies grows, so does the need for accurate, sensitive in-vitro methods of assessing T cell-mediated cytotoxicity prior to clinical testing. BioIVT has been working closely with partners in the industry to ensure that its clients have access to the best models available.”

BioIVT will be presenting its latest results during the following sessions:

Sunday, Apr. 15
3:30 - 4:30 pm

Presentation - “Automated, Image-based Solutions to Assess T Cell Activation and Cell-mediated Cytotoxicity using 2D and 3D Target Cell Models”

Presenters - Brad Larson, BioTek Instruments, Inc.; Glauco Souza, Greiner Bio-One; and Wini Luty, BioIVT; with support from Adipogen Life Sciences

This session will cover phenotypic and quantitative image-based methods for assessing T cell activation, T cell: target cell interactions, and induction of target cell death. Data will be presented from 2D and 3D target cell models, and T cells activated, in the presence of target cells, using general and directed methods.

Monday, Apr. 16
1 - 5 pm

Poster 2548 / 6 - “An Image-based Method to Detect and Quantify T Cell-mediated Cytotoxicity of 2D and 3D Target Cell Models”

BioIVT PHASEZERO® consultants will also be available to answer technical questions in booth #1831.

For more information about the AACR Annual Meeting, please visit http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=136#.Ws5VX5qG_WN

Interested parties can also attend a complimentary one-hour webinar entitled ”Development of a Genetically-defined 3D Lung Cancer Model for Functional and Efficacy Studies,” which will be co-hosted by BioIVT and Cellaria at 11 am EST on Wednesday, Apr. 25.

Webinar presenters Elin Agoston from Cellaria, and Kathryn Bagot from BioIVT, will discuss the benefits of using 3D models composed of primary, genetically-defined cells in drug efficacy studies. These models can also be used in downstream applications, such as qPCR and immunostaining, in response to chemotherapeutic agents.

Register at https://join.onstreammedia.com/register/95965183/bioivtcellaria#registration.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease-state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.